Pure Bioscience Inc (PURE) financial statements (2021 and earlier)

Company profile

Business Address 9669 HERMOSA AVENUE
RANCHO CUCAMONGA, CA 91730
State of Incorp. DE
Fiscal Year End July 31
SIC 289 - Miscellaneous Chemical Products (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

1/31/2021
TTM
7/31/2020
7/31/2019
7/31/2018
7/31/2017
7/31/2016
7/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3401251
Cash and cash equivalents3401251
Receivables0100000
Inventory, net of allowances, customer advances and progress billings1100000
Inventory1100000
Prepaid expense0000000
Other undisclosed current assets0000000
Total current assets:4611262
Noncurrent Assets
Property, plant and equipment1000100
Intangible assets, net (including goodwill)0011111
Intangible assets, net (excluding goodwill)0011111
Total noncurrent assets:1111111
TOTAL ASSETS:5623483
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1211111
Accounts payable1111001
Accrued liabilities0000000
Debt   1   
Derivative instruments and hedges, liabilities    220
Restructuring reserve    000
Total current liabilities:1211331
Noncurrent Liabilities
Liabilities, other than long-term debt  00000
Deferred revenue and credits000
Deferred rent credit  00
Total noncurrent liabilities:  00000
Total liabilities:1211331
Stockholders' equity
Stockholders' equity attributable to parent5511152
Common stock1111110
Additional paid in capital12812712411811010891
Accumulated deficit(124)(123)(123)(117)(109)(103)(89)
Total stockholders' equity:5511152
TOTAL LIABILITIES AND EQUITY:5623483

Income statement (P&L) ($ in millions)

1/31/2021
TTM
7/31/2020
7/31/2019
7/31/2018
7/31/2017
7/31/2016
7/31/2015
Revenues9722211
Revenue, net211
Cost of revenue
(Cost of Goods and Services Sold)
(4)(3)(1)(1)(0)(0)(0)
Gross profit:5411210
Operating expenses(4)(4)(7)(9)(8)(8)(8)
Other undisclosed operating income (loss)(0) 11000
Operating income (loss):10(6)(7)(6)(7)(8)
Nonoperating income (expense)00(1)(0)(0)(7)0
Investment income, nonoperating   0(0)(5)0
Other nonoperating income 000000
Interest and debt expense(0)(0)(0)(0)(0)(0)(0)
Income (loss) from continuing operations before income taxes:10(7)(7)(6)(14)(8)
Income tax expense      (0)
Net income (loss):10(7)(7)(6)(14)(8)
Other undisclosed net income (loss) attributable to parent(0) 00000
Net income (loss) available to common stockholders, diluted:10(7)(7)(6)(14)(8)

Comprehensive Income ($ in millions)

1/31/2021
TTM
7/31/2020
7/31/2019
7/31/2018
7/31/2017
7/31/2016
7/31/2015
Net income (loss):10(7)(7)(6)(14)(8)
Comprehensive income (loss), net of tax, attributable to parent:10(7)(7)(6)(14)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: